Naurex to Present at the 32nd Annual J.P. Morgan Healthcare Conference

EVANSTON, Ill., Jan. 9, 2014 /PRNewswire/ -- Naurex Inc. today announced that Norbert G. Riedel, Ph.D., long-term board member and newly-appointed president and chief executive officer of Naurex, will present at the 32nd Annual J.P. Morgan Healthcare Conference at 3 p.m. PST on Tuesday, January 14, 2014 at the Westin St. Francis Hotel in San Francisco. Dr. Riedel will provide an overview of the company and discuss its two clinical-stage rapid-acting antidepressant drug candidates, GLYX-13 and NRX-1074.

About Naurex
Naurex is a clinical-stage biopharmaceutical company developing products to treat diseases of the central nervous system (CNS). The company's lead compound, GLYX-13, has shown promising rapid-acting antidepressant activity with excellent safety and no psychomimetic side effects in a Phase 2a clinical trial. GLYX-13 is currently in a Phase 2b repeat dose study as adjunctive therapy for major depressive disorder. Naurex's 2nd-generation antidepressant, NRX-1074, is in Phase 1 clinical trials. Naurex's proprietary platform is focused on discovering novel compounds that act at the NMDA receptor to modulate neuronal plasticity and hold therapeutic potential for a number of CNS indications. For more information, visit

Naurex Inc.
Ashish Khanna
Vice President, Corporate Development
T: 847-871-0377

Media and Investors
Russo Partners, LLC
Robert Flamm, Ph.D.                             
Matt Middleman, M.D.
T: 212-845-4226                                     
T: 212-845-4272 

SOURCE Naurex Inc.


More by this Source

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.